ACHV:NSD-Achieve Life Sciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.40

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

1.75M

Average Target Price

USD 2.00 (+402.51%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. Its product candidate include cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. The company has license agreements with Sopharma AD and University of Bristol; and a strategic collaboration with National Institutes of Health for the development of cytisinicline for smoking cessation. Achieve Life Sciences, Inc. was incorporated in 1991 and is based in Vancouver, Canada.

Company Website : http://www.achievelifesciences.com

Address : 1040 West Georgia Street, Vancouver, BC, Canada, V6E 4H1

Employees : 14

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.42

52 Week High : 2.51

Short Ratio : 2.08

52 Week Low : 0.23

Shorted Shares : 2,197,433

200 Day Moving Average : 0.44

Shorted Shares Previous Month : 1,000,190

50 Day Moving Average : 0.42

Shares Held By Insiders : 11.28%

Short Percentage : 6.00%

Shares Held by Institutions : 17.06%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD76.34B 51.29 38.52
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD63.70B 32.18 22.32
SGEN Seattle Genetics, Inc

N/A

 USD30.18B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD24.03B 10.20 8.76
MRNA Moderna, Inc

N/A

 USD23.24B N/A N/A
GMAB Genmab A/S

N/A

 USD22.91B 49.21 4.63
BMRN BioMarin Pharmaceutical Inc

N/A

 USD22.80B 201.29 120.75
INCY Incyte Corporation

N/A

 USD22.77B 47.64 35.20
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD18.63B N/A N/A
BGNE BeiGene, Ltd

N/A

 USD15.57B N/A N/A

ETFs Containing ACHV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.91% 25% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.91% 25% F 32% F
Trailing 12 Months  
Capital Gain -77.39% 5% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.39% 5% F 3% F
Trailing 5 Years  
Capital Gain -98.38% 9% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.38% 9% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -5.29% 61% D- 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.29% 60% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 56.15% 42% F 21% F
Risk Adjusted Return -9.41% 59% F 38% F
Market Capitalization 0.02B 5% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.80 64% D 88% B+
Price/Book Ratio 1.01 95% A 72% C-
Price / Cash Flow Ratio -1.02 15% F 62% D-
EV/EBITDA 0.36 54% F 93% A
Management Effectiveness  
Return on Equity -109.72% 29% F 12% F
Return on Invested Capital -97.65% 27% F 9% F
Return on Assets -55.96% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.08 58% F 55% F
Short Percent 5.91% 47% F 34% F
Beta 1.42 58% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.